B cell-specific lentiviral gene therapy (Seattle Children's Hospital)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameB cell-specific lentiviral gene therapy (Seattle Children's Hospital)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsAgammaglobulinemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeattle Children'S Hospital
Active IndicationsN/A
Inactive IndicationsAgammaglobulinemia

Other Information

ATC CodeN/A
Related LinksN/A